MedTrace Logo

PK Study to Evaluate the Effect of PLC on Healthy Chinese Subjects by Multiple-doses

NCT02786043 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-05-30

No results posted yet for this study

Summary

The main objective is to evaluate the effect of Propionyl-L-Carnitine Hydrochloride on clinical pharmacokinetic characteristics and its effect of clinical pharmacokinetic characteristics and safety on healthy Chinese subjects to provide a basis for market authorization registration

Conditions

  • Peripheral Arterial Diseases

Interventions

DRUG

Propionyl-L-Carnitine Hydrochloride

1g twice a day on first 4 days and 1g/ day on day 5 during Phase III

Sponsors & Collaborators

  • Lee's Pharmaceutical Limited

    lead INDUSTRY

Principal Investigators

  • Heng-yan Qu · National Clinical Trial Institution of Affiliated Hospital of Military Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-11-30
Completion
2016-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02786043 on ClinicalTrials.gov